Skip to main content
SpringerLink
Log in

Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives

  • Review Article
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Nitric oxide donors have been commonly used in the therapy of cardiovascular disease for more than 150 years. In spite of this longevity and the popularity of their use, it appears somewhat paradoxical that there is no current consistent use among cardiologists, as to both their indications and their optimal mode of administration. In part this results from their contradictory pharmacodynamics: when given acutely, their effectiveness is undisputable; however, their long-term efficacy is potentially limited by the development of tolerance and the induction of endothelial dysfunction, which may have negative prognostic implications. This review reports recent biochemical and pathophysiological acquisitions, re-examines the role of nitrates and other nitric oxide donors in cardiovascular medicine, comparing and commenting on international guidelines; and highlights areas of uncertainty, where more clinical research with these drugs would still be warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med. 1995;155:357–64.

    Article  PubMed  CAS  Google Scholar 

  2. Bauer JA, Booth BP, Fung HL. Nitric oxide donors: biochemical pharmacology and therapeutics. Adv Pharmacol. 1995;34:361–81.

    Article  PubMed  CAS  Google Scholar 

  3. De Caterina R. Antiplatelet effects of nitrate derivatives. G Ital Cardiol. 1991;21:529–41.

    PubMed  Google Scholar 

  4. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation. 2002;106:2404–8.

    Article  PubMed  Google Scholar 

  5. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618–28.

    Article  PubMed  Google Scholar 

  6. Dawn B, Bolli R. Role of nitric oxide in myocardial preconditioning. Ann N Y Acad Sci. 2002;962:18–41.

    Article  PubMed  CAS  Google Scholar 

  7. Jneid H, Chandra M, Alshaher M, et al. Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation. 2005;111:2565–71.

    Article  PubMed  CAS  Google Scholar 

  8. Gori T, Di Stolfo G, Sicuro S, et al. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145–50.

    Article  PubMed  CAS  Google Scholar 

  9. Effect of nicorandil on coronary events in patients with stable angina. the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–75.

    Article  Google Scholar 

  10. Gori T, Parker JD. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol. 2008;52:251–4.

    Article  PubMed  CAS  Google Scholar 

  11. Nakamura Y, Moss A, Brown M, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:577–85.

    Article  PubMed  CAS  Google Scholar 

  12. Chen Z, Zhang J, Stamler J. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002;99:8306–11.

    Article  PubMed  CAS  Google Scholar 

  13. Katsuki S, Murad F. Regulation of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate levels and contractility in bovine tracheal smooth muscle. Mol Pharmacol. 1977;13:330–41.

    PubMed  CAS  Google Scholar 

  14. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985;76:703–8.

    Article  PubMed  CAS  Google Scholar 

  15. Zhou RH, Frishman WH. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? Cardiol Rev. 2010;18:198–203.

    Article  PubMed  Google Scholar 

  16. Zimarino M, Ausiello A, Contegiacomo G, et al. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol. 2006;48:59–65.

    Article  PubMed  Google Scholar 

  17. Caramori P, Adelman A, Azevedo E, Newton G, Parker A, Parker J. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol. 1998;32:1969–74.

    Article  PubMed  CAS  Google Scholar 

  18. Kurz M, Lamping K, Bates J, Eastham C, Marcus M, Harrison D. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res. 1991;68:847–55.

    PubMed  CAS  Google Scholar 

  19. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. Circ Res. 1968;22:649–59.

    PubMed  CAS  Google Scholar 

  20. Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther. 2007;116:287–305.

    Article  PubMed  CAS  Google Scholar 

  21. Chirkov YY, Holmes AS, Willoughby SR, et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851–7.

    Article  PubMed  CAS  Google Scholar 

  22. Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol. 2004;93:1438–40. A10.

    Article  PubMed  CAS  Google Scholar 

  23. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–93.

    Article  PubMed  CAS  Google Scholar 

  24. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997;10:735–42.

    Article  PubMed  CAS  Google Scholar 

  25. Horowitz JD. Amelioration of nitrate tolerance: matching strategies with mechanisms. J Am Coll Cardiol. 2003;41:2001–3.

    Article  PubMed  CAS  Google Scholar 

  26. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810–5.

    PubMed  CAS  Google Scholar 

  27. Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123:2132–44.

    Article  PubMed  Google Scholar 

  28. Towell 3rd JF, Barboriak JJ, Townsend WF, Kalbfleisch JH, Wang RI. Erythrocyte aldehyde dehydrogenase: assay of a potential biochemical marker of alcohol abuse. Clin Chem. 1986;32:734–8.

    PubMed  CAS  Google Scholar 

  29. Mackenzie IS, Maki-Petaja KM, McEniery CM, et al. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005;25:1891–5.

    Article  PubMed  CAS  Google Scholar 

  30. D'Souza Y, Dowlatshahi S, Bennett BM. Changes in Aldehyde Dehydrogenase 2 Expression in Rat Blood Vessels during Glyceryl Trinitrate Tolerance Development and Reversal. Br J Pharmacol 2011.

  31. Uxa A, Thomas GR, Gori T, Parker JD. Standard versus low-dose transdermal nitroglycerin: differential effects on the development of tolerance and abnormalities of endothelial function. J Cardiovasc Pharmacol. 2010;56:354–9.

    Article  PubMed  CAS  Google Scholar 

  32. Henry PJ, Drummer OH, Horowitz JD. S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol. 1989;98:757–66.

    PubMed  CAS  Google Scholar 

  33. Gori T, Daiber A. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs. 2009;9:7–15.

    PubMed  CAS  Google Scholar 

  34. Thadani U. Role of nitrates in angina pectoris. Am J Cardiol. 1992;70:43B–53B.

    Article  PubMed  CAS  Google Scholar 

  35. Gibbons R, Abrams J, Chatterjee K. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—Summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159–68.

    Article  PubMed  Google Scholar 

  36. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81.

    Article  PubMed  Google Scholar 

  37. Izumiya Y, Kojima S, Araki S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis. 2011;214:415–21.

    Article  PubMed  CAS  Google Scholar 

  38. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–304.

    Article  PubMed  Google Scholar 

  39. Yamabe H, Namura H, Yano T, et al. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther. 1995;9:755–61.

    Article  PubMed  CAS  Google Scholar 

  40. Zimarino M, Prati F, Stabile E, et al. Optical coherence tomography accurately identifies intermediate atherosclerotic lesions–an in vivo evaluation in the rabbit carotid artery. Atherosclerosis. 2007;193:94–101.

    Article  PubMed  CAS  Google Scholar 

  41. Silber S, Albertsson P, Aviles FF. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–47.

    Article  PubMed  Google Scholar 

  42. Franciosa J, Goldsmith S, Cohn J. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med. 1980;69:559–66.

    Article  PubMed  CAS  Google Scholar 

  43. Leier C, Huss P, Magorien R, Unverferth D. Improved execise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation. 1983;67:817–22.

    Article  PubMed  CAS  Google Scholar 

  44. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–52.

    Article  PubMed  CAS  Google Scholar 

  45. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.

    Article  PubMed  CAS  Google Scholar 

  46. Rector TS, Johnson G, Dunkman WB. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI71–7.

    PubMed  CAS  Google Scholar 

  47. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.

    Article  PubMed  CAS  Google Scholar 

  48. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187–94.

    Article  PubMed  CAS  Google Scholar 

  49. Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865–74.

    Article  PubMed  CAS  Google Scholar 

  50. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–235.

    Article  PubMed  Google Scholar 

  51. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.

    Article  PubMed  CAS  Google Scholar 

  52. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230–68.

    PubMed  Google Scholar 

  53. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e523–661.

    Article  PubMed  Google Scholar 

  54. DePace NL, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med. 1982;142:1806–9.

    Article  PubMed  CAS  Google Scholar 

  55. Roubin GS, Harris PJ, Eckhardt I, Hensley W, Kelly DT. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust N Z J Med. 1982;12:598–602.

    Article  PubMed  CAS  Google Scholar 

  56. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988;1:1088–92.

    Article  PubMed  CAS  Google Scholar 

  57. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115–22.

    Google Scholar 

  58. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669–85.

    Google Scholar 

  59. Cleland JG. ISIS-4 study. Lancet. 1995;345:1372–3. author reply 4–5.

    PubMed  CAS  Google Scholar 

  60. Thadani U. Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther. 1997;11 Suppl 1:213–8.

    Article  PubMed  CAS  Google Scholar 

  61. Cotter G, Faibel H, Barash P, et al. High-dose nitrates in the immediate management of unstable angina: optimal dosage, route of administration, and therapeutic goals. Am J Emerg Med. 1998;16:219–24.

    Article  PubMed  CAS  Google Scholar 

  62. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.

    Article  PubMed  CAS  Google Scholar 

  63. Horowitz JD, Henry CA, Syrjanen ML. Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris. Eur Heart J. 1988;9:95–100. Suppl A.

    PubMed  Google Scholar 

  64. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–292.

    Article  PubMed  Google Scholar 

  65. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296–329.

    Article  PubMed  Google Scholar 

  66. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–45.

    Article  PubMed  Google Scholar 

  67. Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev. 2009;14:299–307.

    Article  PubMed  CAS  Google Scholar 

  68. Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther. 2004;9:227–41.

    Article  PubMed  CAS  Google Scholar 

  69. Beltrame JF, Zeitz CJ, Unger SA, et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4:271–9.

    Article  PubMed  CAS  Google Scholar 

  70. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.

    Article  PubMed  CAS  Google Scholar 

  71. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.

    Article  PubMed  CAS  Google Scholar 

  72. Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. Eur Heart J. 2001;22:1642–81.

    Article  PubMed  CAS  Google Scholar 

  73. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res. 2004;94:7–16.

    Article  PubMed  CAS  Google Scholar 

  74. Needleman P. Tolerance to the vascular effects of glyceryl trinitrate. J Pharmacol Exp Ther. 1970;171:98–102.

    PubMed  CAS  Google Scholar 

  75. Bussmann WD, Passek D, Seidel W, Kaltenbach M. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation. 1981;63:615–22.

    Article  PubMed  CAS  Google Scholar 

  76. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation. 1988;78:906–19.

    Article  PubMed  CAS  Google Scholar 

  77. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group Jpn Circ J. 1996;60:779–88.

    CAS  Google Scholar 

  78. Kanamasa K, Naito N, Morii H, et al. Eccentric dosing of nitrates does not increase cardiac events in patients with healed myocardial infarction. Hypertens Res. 2004;27:563–72.

    Article  PubMed  CAS  Google Scholar 

  79. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103:2072–7.

    PubMed  Google Scholar 

  80. Gori T, Floras JS, Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol. 2002;40:2000–5.

    Article  PubMed  CAS  Google Scholar 

  81. Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol. 1997;29:941–7.

    Article  PubMed  CAS  Google Scholar 

  82. Horowitz JD, Henry CA, Syrjanen ML, et al. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 1988;77:787–94.

    Article  PubMed  CAS  Google Scholar 

  83. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13:786–95.

    Article  PubMed  CAS  Google Scholar 

  84. Parker JD. Nitrate therapy for stable angina pectoris. N Eng J Med. 1998;338:520–31.

    Article  CAS  Google Scholar 

  85. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282–8.

    PubMed  CAS  Google Scholar 

  86. Gruhn N, Aldershvile J, Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol. 2001;416:245–9.

    Article  PubMed  CAS  Google Scholar 

  87. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244–8.

    Article  PubMed  CAS  Google Scholar 

  88. Towell J, Garthwaite T, Wang R. Erythrocyte aldehyde dehydrogenase and disulfiram-like side effects of hypoglycemics and antianginals. Alcohol Clin Exp Res. 1985;9:438–42.

    Article  PubMed  CAS  Google Scholar 

  89. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170–5.

    Article  PubMed  CAS  Google Scholar 

  90. King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261–95.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cardiology, “G. d’Annunzio” University - Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, 66013, Chieti, Italy

    Francesco Iachini Bellisarii, Francesco Radico, Francesca Muscente & Raffaele De Caterina

  2. Department of Medicine, The Queen Elizabeth Hospital, Adelaide, Australia

    John Horowitz

Authors
  1. Francesco Iachini Bellisarii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Radico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Muscente
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raffaele De Caterina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raffaele De Caterina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iachini Bellisarii, F., Radico, F., Muscente, F. et al. Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives. Cardiovasc Drugs Ther 26, 55–69 (2012). https://doi.org/10.1007/s10557-011-6354-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-011-6354-0

Key words

Search

Navigation